Affiliation: Bristol-Myers Squibb
- Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorderVladimir Coric
Bristol Myers Squibb Company, Neuroscience Global Clinical Research, Wallingford, Connecticut 06492, USA
Depress Anxiety 27:417-25. 2010..This study was designed to determine the safety and efficacy of pexacerfont, a selective CRF-1 receptor antagonist, in the treatment of generalized anxiety disorder (GAD)...
- Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer diseaseVladimir Coric
Neuroscience Global Clinical Research, Bristol Myers Squibb, Wallingford, Connecticut 06492, USA
Arch Neurol 69:1430-40. 2012..To assess the safety, tolerability, and pharmacokinetic and pharmacodynamic effects of the -secretase inhibitor avagacestat in patients with mild to moderate Alzheimer disease (AD)...